Pfizer's 7% dividend yield ranks among the highest in the healthcare sector, nearly triple the average of the S&P 500. The payout ratio has improved to 89% from over 100% in recent quarters, but ...

On April 13, UBS Group AG raised its price recommendation on Pfizer Inc. (NYSE:PFE) to $27 from $25. It maintained a Neutral ...

Pfizer is seeking drug development partnerships with Chinese biotech companies as local players gain ground on Western peers.

Pfizer (NYSE: PFE) is a high-yielding stock that's trading at a low valuation. The problem is, it's been that way for some time now. The stock's lack of movement in one direction or another seems to ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

Pfizer possesses several qualities that make it attractive when market volatility is high. The stock has a low forward earnings multiple and a higher -- yet still attractive -- EV-to-EBITDA ratio.

My very first article on Pfizer Inc. (PFE) stock came out in mid-February 2024 with a "Buy" rating as I was arguing that PFE's depressed valuation and strong product pipeline made it "the ultimate ...

Pfizer is behind Eli Lilly and Novo Nordisk in the GLP-1 race, but long-term investors shouldn't count the company out.

AMC Entertainment (AMC) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

Pfizer is closing its South San Francisco research site as part of a wider expense reduction effort. Staff at the site are ...

Shares of the pharmaceutical giant trade at less than 9 times its future earnings. Investors are likely concerned about upcoming patent cliffs that may weigh down its financials. However, the company ...